Ninety-three percent of oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC test

Original source here.

OncoHost, a technology company, announced the publication of a study in Clinical Lung Cancer demonstrating the impact of its PROphetNSCLC test on first-line treatment decisions for metastatic non-small cell lung cancer patients.